Your Health, We Care
Lucius Pharmaceuticals has successfully launched lorlatinib, a targeted therapy for lung cancer, especially for patients with non-small cell lung cancer with ALK gene mutations. The drug has been licensed and certified by the Lao government and is recognized in many countries and regions around the world, providing more treatment options for cancer patients.
